TABLE 1.

Registry cohort study characteristics

Gender (n,%)
Male	36 (58.06%)
Female	26 (41.94%)
Age at study enrollment (median, IQR)	41 (30–56)
Age at diagnosis of WD (median, IQR)	19 (11–25)
Treatment duration (median, IQR)	19.5 (7–35)
Major depressive disorder (n) (MINI-7)	22 (37.29%)
PHQ 9 score (median, IQR)	3 (1–6)
Cognitive impairment (n) (MOCA <26)	28 (47.46%)
Neurological symptoms (n) (UWDRS >0)	50 (80.65%)
Cirrhosis (n)*	12 (19.67%)
Current WD medication (n)	WD treatment duration median (IQR)	Previous different WD medication regimen (n)
d-Penicillamine n = 8	37 (4,41)	Y = 0, N = 8
Trientine n = 20	23.5 (8,43)	Y = 14, N = 6
Zinc n = 27	17 (12,30)	Y = 25, N = 10
Investigational n = 1	3 (3,3)	Y = 0, N = 1
Chelator and zinc† = 5	26 (14,29)	Y = 5, N = 1

IQR = interquartile range; MINI = Mini-International Neuropsychiatric Interview; MOCA = Montreal Cognitive Assessment; PHQ = Patient Health Questionnaire; UWDRS = United Wilson Disease Rating Scale; WD = Wilson disease.

^*See appendix for cirrhosis diagnostic algorithm.

^†Chelator = d-Penicillamine or Trientine